RZLT 241115 2.50C (RZLT241115C2500) Stock Options, News & Quotes

2.90
0.000.00%

15min DelayClose Nov 4 15:56 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Bigmoney Dreamer

Oct 20 18:07

$Rezolute (RZLT.US)$ 👀 mediocre catalyst

Jaguar8

Sep 9 06:33

NEWS

$Rezolute (RZLT.US)$
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Rezolute, Inc. (Nasdaq: RZLT) announced that the FDA has lifted partial clinical holds on RZ358 (ersodetug), their potential treatment for hypoglycemia caused by congenital hyperinsulinism (HI). This allows the company to include U.S. participants in their ongoing global Phase 3 sunRIZE study. Rezolute plans to begin U.S. enrollm...

Trytosaveabit

Sep 9 06:31

News

$Rezolute (RZLT.US)$ Reuters· 1 min ago
FDA Lifts Partial Clinical Holds on Rz358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

steven smith38

Aug 5 06:40

$Apple (AAPL.US)$ Update
$Rezolute (RZLT.US)$ Reuters· 6 mins ago
Rezolute Announces FDA Clearance of Ind Application for Phase 3 Registrational Study of Rz358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

steven smith38

Aug 5 06:40

Update
$Rezolute (RZLT.US)$ Reuters· 6 mins ago
Rezolute Announces FDA Clearance of Ind Application for Phase 3 Registrational Study of Rz358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism